ArticleHaematologica2013
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
Article in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04889729 (Genomic and Personalized Medicine for All), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genomic and Personalized Medicine for All (GENOMED4ALL): Application of Artificial Intelligence to Improve Disease Classification and Prognosis in Myelodysplastic Syndrome.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.
- Guideline
- The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.American journal of hematology · 2019Trial
- Trial
- Article
- Reframing-renaming(?)-myelodysplastic syndromes/neoplasms and clonal hematopoiesis of indeterminate potential.Leukemia · 2026Review
- Morphologic findings and mutational profiles of myelodysplastic neoplasms with normal versus abnormal karyotype.Journal of hematopathology · 2026Article
- WT1 as a Biomarker in Myelodysplastic Neoplasms: Clinical Correlations and Preliminary Data from an Iranian Cohort.International journal of hematology-oncology and stem cell research · 2026Article
- Article
- How I treat higher-risk MDS.Blood · 2025Review
- Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.Leukemia · 2025Article
- Standardized bone marrow assessment, risk variables, and survival in dogs with myelodysplastic syndrome and acute myeloid leukemia.Veterinary pathology · 2025Article
- Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes.Pathology oncology research : POR · 2024Article
- Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.Blood advances · 2023Article
- Article
- Proliferative and anti-apoptotic fractions in maturing hematopoietic cell lineages and their role in homeostasis of normal bone marrow.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2022Article
- "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?Leukemia · 2022Review
- Article
- A geno-clinical decision model for the diagnosis of myelodysplastic syndromes.Blood advances · 2021Article
- The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.Blood advances · 2021Review
- Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is uncertain and its assessment was the major aim of this study. The different peripheral blood and bone marrow variables required for an adequate morphological classification were blindly evaluated by four cytomorphologists in samples from 50 patients with myelodysplastic syndromes. The degree of agreement among observers was calculated using intraclass correlation coefficient and the generalized kappa statistic for multiple raters. The degree of agreement for the percentages of blasts in bone marrow and peripheral blood, ring sideroblasts in bone marrow, and erythroid, granulocytic and megakaryocytic dysplastic cells was strong (P<0.001 in all instances). After stratifying the percentages according to the categories required for the assignment of World Health Organization subtypes, the degree of agreement was not statistically significant for cases with 5-9% blasts in bone marrow (P=0.07), 0.1-1% blasts in peripheral blood (P=0.47), or percentage of erythroid dysplastic cells (P=0.49). Finally, the interobserver concordance for World Health Organization-defined subtypes showed a moderate overall agreement (P<0.001), the reproducibility being lower for cases with refractory anemia with excess of blasts type 1 (P=0.05) and refractory anemia with ring sideroblasts (P=0.09). In conclusion, the reproducibility of the World Health Organization 2008 classification for myelodysplastic syndromes is acceptable but the defining criteria for blast cells and features of erythroid dysplasia need to be refined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.